Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Myeloma
•
Hematology
•
Transplant nephrology
•
Multiple Myeloma
Would you consider pursuing renal transplantation in a patient with multiple myeloma?
Related Questions
What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?
How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?
What is your approach to bone imaging in MGUS?
What is your management approach for CAR-T induced motor neurologic deficits (cyclophosphamide/IVIG/Steroids, etc) and any prophylactic approach to an early, rapid rise in absolute lymphocyte count post CAR-T infusion?
How do you evaluate a patient with MGUS and peripheral neuropathy?
How (and when) is primary refractory AL amyloidosis defined following D-CyBorD treatment? Is there a threshold of biomarker reduction following 1-2 cycles that, if not met, should prompt early consideration of treatment change?
For a patient with a metastatic solid tumor in remission on a checkpoint inhibitor who also has R/R multiple myeloma, would you feel comfortable with a bispecific T-cell engager antibody?
Are you still recommending autologous stem cell transplantation (ASCT) for all eligible myeloma patients who achieve remission after induction with a quadruplet regimen?
How do you approach second-line options for relapsed myeloma after front-line quadruplet therapy?
When, if ever, would you select a three-drug regimen instead of four-drug regimen in patients with newly diagnosed Multiple Myeloma?
